<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865836</url>
  </required_header>
  <id_info>
    <org_study_id>ATB200-11</org_study_id>
    <nct_id>NCT03865836</nct_id>
  </id_info>
  <brief_title>Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease</brief_title>
  <official_title>Named Patient or Compassionate Use for Treatment Use of ATB200/AT2221 for Patients With Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <brief_summary>
    <textblock>
      This is an expanded access program (EAP) for eligible participants designed to provide access
      to ATB200/AT2221.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This program is being offered on a patient by patient basis and will require company, IRB/IEC
      and single patient IND approval.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Pompe Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATB200</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT2221</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have a diagnosis of Pompe disease based on documentation of one of the
             following:

               1. deficiency of GAA enzyme

               2. GAA genotyping

          2. Patient does not currently qualify for an Amicus sponsored on-going clinical trial or
             is declining on currently approved ERT (e.g. Myozyme)

          3. The patient must be willing to receive treatment with ATB200/AT2221 via this program,
             which includes signing an authorization form for sharing clinical data with Amicus
             Therapeutics, and its agent Early Access Care LLC.

        Exclusion Criteria:

          1. Patient, whether male or female, is planning to conceive a child during the treatment
             program.

          2. Patient has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa,
             or AT2221

          3. Patient has a medical or any other extenuating condition or circumstance that may, in
             the opinion of the investigator, pose an undue safety risk to the subject or
             compromise his/her ability to comply with or adversely impact protocol requirements.

          4. Patient has received any gene therapy at any time.

          5. Concomitant use of miglitol (eg, Glyset), non-AT2221 form of miglustat (eg, Zavesca),
             acarbose (eg, Precose or Glucobay), voglibose (eg, Volix, Vocarb, or Volibo)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>For Site</last_name>
    <phone>609-662-2000</phone>
    <email>PompeSiteInfo@amicusrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For Patient</last_name>
    <phone>609-662-2000</phone>
    <email>patientadvocacy@amicusrx.com</email>
  </overall_contact_backup>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03729362?term=ATB200-03&amp;rank=1</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>expanded access</keyword>
  <keyword>compassionate use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

